Jump to content

KRAS G12A


JC63

Recommended Posts

Hello Everyone,

I was diagnosed with squamous cell lung cancer in the summer of 2019, which I had surgery for. I recently discovered they did testing and I have the KRAS G12A (biomarker/gene/mutation, not sure what it is considered). From what I've read, there isn't really any immunotherapy for this, just chemo. I haven't had a recurrence yet, but didn't do well with the chemo after surgery. I only made it through two rounds of cisplatin and gemcitabine before I became toxic...(hearing loss/tinnitus mostly). I was wondering if anyone else has this mutation, if so, what options were you given?

Thanks much,

JC63

Link to comment
Share on other sites

Hi, JC, 

I'm under the impression that for mutations that are not "actionable" (i.e., no targeted therapy exists), the mutation is pretty much irrelevant to the treatments available or offered. Maybe I'm wrong about that--if I am, someone please correct me.

Link to comment
Share on other sites

JC,

When the KRAS gene in your DNA acts abnormally it can be the cause of lung cancer. It is found in about 30% of non small cell lung cancer (NSCLC) adenocarcinoma and 5% NSCLC squamous cell. The most common form is KRAS G12A. Some presentations of adenocarcinoma are treatable with targeted therapy. Unfortunately, no targeted therapy has yet been discovered for KRAS. More importantly, no squamous cell lung cancer yet responds to targeted therapy.

But, immunotherapy is not targeted therapy and many types are now available to treat both squamous cell and adenocarcinoma regardless if the KRAS G12A gene mutation is present. I wouldn't know why it wouldn't be effective if you were to have a recurrence. That is a question for your doctor.

But happily, you have not had a recurrence and you won't get one!

Welcome here.

Stay the course.

Tom

Link to comment
Share on other sites

 

Thank you Tom and LexiCat....That does clear up a lot! I wasn't sure the difference between immunotherapy and targeted therapy. My oncologist made it sound like chemo was my only option, and that really scared me after the awful side effects last time around. 

Link to comment
Share on other sites

  • 1 year later...

As we know that KRAS D12C is a drive mutation for NSCLC. Your case is sarcoma lung cancer with KRAS G12A  mutation. It is different type of mutation, and the treatment should be different from that of NSCLC. We do not know if KESG12A is a drive mutation in Sarcoma lung cancer, but it is a KRAS mutation, and is response for tumorigenesis. The latest research results indicate that clinical utility of dual SHP2/MEK inhibition as a targeted therapy would be effective in treatment of KRAS-mutant cancer, specifically for lung cancer,

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.